NASDAQ: GLUEMonte Rosa Therapeutics Inc Stock Ownership - Who owns Monte Rosa Therapeutics?
Insider buying vs selling
Have Monte Rosa Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Versant Venture Capital VI LP | 10% Owner | 2024-10-29 | 52,305 | $9.08 | $475.03kSell |
| Versant Venture Capital VI LP | 10% Owner | 2024-10-29 | 15,600 | $9.41 | $146.80kSell |
| Versant Venture Capital VI LP | 10% Owner | 2024-10-28 | 89,990 | $9.66 | $869.21kSell |
| Versant Venture Capital VI LP | 10% Owner | 2024-09-20 | 1,132,566 | $6.53 | $7.40MSell |
| Versant Venture Capital VI LP | 10% Owner | 2024-09-13 | 9,269 | $6.16 | $57.10kSell |
| Versant Venture Capital VI LP | 10% Owner | 2024-09-12 | 16,047 | $6.00 | $96.31kSell |
| Versant Venture Capital VI LP | 10% Owner | 2024-09-11 | 541,897 | $6.00 | $3.25MSell |
| Edmund Dunn | Principal Accounting Officer | 2024-07-05 | 1,610 | $3.83 | $6.17kSell |
| Edmund Dunn | Principal Accounting Officer | 2024-06-03 | 1,207 | $4.04 | $4.88kSell |
GLUE insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when GLUE insiders and whales buy or sell their stock.
GLUE Shareholders
What type of owners hold Monte Rosa Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Bradley J. Phd Bolzon | 14.48% | 8,897,053 | $83.99M | Insider |
| Versant Venture Capital VI LP | 12.62% | 7,750,860 | $73.17M | Insider |
| Anthony A. Florence Jr. | 12.52% | 7,692,298 | $72.62M | Insider |
| Peter W. Sonsini | 12.52% | 7,692,298 | $72.62M | Insider |
| Carmen Chang | 12.52% | 7,692,298 | $72.62M | Insider |
| Scott D. Sandell | 12.52% | 7,692,298 | $72.62M | Insider |
| Forest Baskett | 12.52% | 7,692,298 | $72.62M | Insider |
| Mohamad Makhzoumi | 12.52% | 7,692,298 | $72.62M | Insider |
| Edward T. Mathers | 12.52% | 7,692,298 | $72.62M | Insider |
| Ali Behbahani | 12.52% | 7,692,298 | $72.62M | Insider |
GLUE vs Biotech Stocks
Monte Rosa Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.